Access to Medicines… Here Again?! – The WTO COVID19 Waiver Ministerial Decision- June 2022 17 Jun 202217 Jun 2022 In a previous piece in the Conversation and on this Blog I predicted that the final outcome of the negotiations on the TRIPS Waiver would end up with a solution…
Access to Medicines… Interview on my Scholarship with Dean Andrew Strauss 29 Jan 2022 Dean Andrew Strauss interviewed me for his podcast On the Witness Stand, about my scholarship on IP and traditional knowledge and IP and climate change and how I ended up…
Access to Medicines… US support for waiving COVID-19 vaccine patent rights puts pressure on drugmakers – but what would a waiver actually look like? 10 May 2021 A COVID-19 surge has pushed hospitals in India beyond their capacity. A stadium in New Delhi was being used as a makeshift ward on May 2, 2021. Getty Images Dalindyebo…
Access to Medicines… A Compulsory License Option for the COVID19 TRIPS Waiver Proposal 15 Apr 202116 Apr 2021 In a recent news piece, I argued that while I support the proposal from India, South Africa and other countries for a temporary waiver of TRIPS obligations, my assessment is…
Access to Medicines… How to get COVID-19 vaccines to poor countries – and still keep patent benefits for drugmakers 15 Apr 202115 Apr 2021 How to get COVID-19 vaccines to poor countries – and still keep patent benefits for drugmakers Hospital staff in Lagos, Nigeria, administer the AstraZeneca vaccine. AP Photo/Sunday Alamba Dalindyebo Shabalala,…
Access to Medicines… Can Countries use TRIPS Article 31 (Compulsory Licensing) to address COVID Vaccine shortages? 23 Feb 2021 (for a longer treatment on the availability of unilateral measures under TRIPS, I recommend Chapter 6 of my PhD Climate Change, Technology Transfer and Intellectual Property: Options for Action at…
Access to Medicines… Can Countries use TRIPS Article 30 to take Unilateral Action to Address COVID Vaccine shortages? 22 Feb 2021 (For a longer treatment on the availability of unilateral measures under TRIPS, I recommend Chapter 6 of my PhD Climate Change, Technology Transfer and Intellectual Property: Options for Action at…
Access to Medicines… Is COVID Manufacturing Capacity actually limited or is Intellectual Property the problem? 19 Feb 2021 Supply of the Moderna and BioNTech/Pfizer (and others) vaccines is likely not to keep up with the supply commitments made by both companies. News reports suggest that they are only…
Technology, Sustainability & Human Rights 